Protagonist Therapeutics

scrabble tiles spelling out psoriasis
Biotech

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.
James Waldron Mar 10, 2025 7:30am
Graphic of a drop of blood made up of small data points and nodes

Takeda's $300M bet on Protagonist's blood cancer drug pays off

Mar 3, 2025 8:45am
On target clinical trial success bullseye score

J&J, Protagonist's oral psoriasis prospect scores in phase 3s

Nov 19, 2024 11:44am
storybook

Takeda plays Protagonist, paying $300M for blood disease pact

Jan 31, 2024 5:41pm
Skin closeup

Protagonist, J&J oral psoriasis efficacy data spur phase 3 plans

Jul 4, 2023 2:50am
JJ logo on building

J&J props up immunology, oncology franchises after R&D overhaul

Apr 18, 2023 11:05am